The invention discloses paenibacillus kribbensis exopolysaccharide and application thereof in prevention and control of iridovirus diseases of micropterus salmoides. The invention provides a paenibacillus kribbensis exopolysaccharide. The paenibacillus kribbensis exopolysaccharide is prepared from a fermentation product of a paenibacillus kribbensis space mutationdelta PS04-17 strain. As a fish feed additive, the paenibacillus kribbensis exopolysaccharide has better in-vivo safety, has a promoting effect on the growth of the largemouth bass, and can promote the growth and weight gain of the largemouth bass and reduce the feed coefficient of the largemouth bass. Meanwhile, as a drug for resisting LMBV virus infection, the compound can inhibit expression of viruses in target tissues, alleviate virus-induced fish body target tissue structure damage and reduce the death rate caused by virus infection. Besides, the paenibacillus kribbensis exopolysaccharide serving as a disease-resistant immunopotentiator can maintain intestinal health of the micropterus salmoides, is simple to prepare, low in cost and easy to obtain in quantity, and provides more products and methods for prevention and control of the iridovirusdisease of the micropterus salmoides.
The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In particular, the disclosure relates to concatemeric mRNA cancer vaccines encoding several cancer epitopes on a single mRNA construct, i.e. poly-epitope mRNA constructs or poly-neo-epitope constructs. The disclosure further relates to p53 and KRAS mutations, as well as incorporation of immune enhancers such as STING, e.g. mRNA constructs further encoding an immune stimulator or adjuvant. The disclosure further relates to inclusion of universal T cell epitopes, such as tetanus or diphtheria toxins to elicit an enhanced immune response.
The composition is prepared from group B meningococcus NHBA recombinant protein, fHbp (V1-V1) recombinant protein and fHbp (V2-V3) recombinant protein obtained through artificial modification, or three corresponding recombinant proteins obtained by further adding P4 signalpeptide on the basis of the group B meningococcus NHBA recombinant protein, the fHbp (V1-V1) recombinant protein and the fHbp (V2-V3) recombinant protein, and animal experiments prove that the composition has good immunogenicity and can be used for preparing the immunopotentiator. The compound can be used for preparing vaccines for preventing group B meningococcus.
The invention discloses an immunogenic composition containing an adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises self-assembled gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the self-assembled gE virus-like nanoparticles are formed by polymerizing and assembling monomers; the monomers include VZV gE, a linkerpeptide (SGS), and a VZV gI polypeptide containing a Th epitope. The immunogenic composition can be applied to varicella-zoster virus vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, and the use of an immunopotentiator in the vaccine can be reduced, so that the clinical side reaction of the vaccine is lower; in addition, the vaccine can induce a gI specific antibody and gI specific CMI reaction, and the effectiveness of the vaccine can be further improved. In short, the immunogenic composition has good clinical application potential.
The invention relates to a fungus-diatom synergistic immunopotentiator for stichopus japonicus, and belongs to the technical field of microbial engineering and echinodermimmunology. The immunopotentiator is a symbiont microsphere taking yarrowia lipolytica and navicula seminuda as main components; the method comprises the following steps: respectively activating yarrowia lipolytica and navicula seminuda, carrying out expanding culture, resuspending, and adjusting the concentrations of a bacterial solution and algae cells; the preparation method comprises the following steps: adding a navicula seminuda concentrated solution and a yarrowia lipolytica suspension into a triangular flask containing a YPD liquid culture medium, adding selenium-containing fucoidanpolysaccharidesulfate accounting for 0.4-1.2% of the total mass of microspheres, carrying out constant-temperature shake culture, filtering by using sterile gauze to obtain microspheres, and flushing by using sterile normal saline to obtain fungus-diatom symbiont microspheres; the yarrowia lipolytica, the navicula seminuda and the selenium-containing fucoidanpolysaccharidesulfate in the prepared immunopotentiator are mutually beneficial and have a synergistic effect, and the non-specific immune function of the stichopus japonicus is comprehensively improved by improving the growth index, enhancing the activity of immune enzyme and digestive enzyme and improving the disease resistance.
The invention discloses a composite adjuvant, and belongs to the field of vaccine adjuvants. The main active components of the composite adjuvant are squalene, polysorbate 80 and monophosphoryl ester A, the composite adjuvant is in an oil-in-water emulsion form, nano-scale emulsion droplet particles are uniformly distributed in a water phase, and the system is stable. The invention also discloses a preparation method of the composite adjuvant based on a stirring method. The composite adjuvant comprehensively utilizes the dual characteristics of the oil-in-water emulsion and the immunopotentiator, and can induce a higher level of immunoreaction when being combined with the antigen, so that the composite adjuvant can be used for preparing vaccines and improving the effectiveness of the vaccines.
The invention belongs to the technical field of drug co-delivery, and particularly relates to a nano-platform based on attenuated bacterial outer membrane vesicles and capable of achieving co-delivery of siRNA and adriamycin and a preparation method of the nano-platform. The preparation method comprises the following steps: synthesizing an ROS response type cationic polymer PTP; the preparation method comprises the following steps: preparing aptamer-DOX; preparing an ROS (reactive oxygen species) response type positive electric nano core PTP / 47aD; extracting and purifying the [delta] msbB OMVs; synthesizing a target functional unit DSPE-PEG2k-Angiopep-2 (Distearoyl PhosphatePolyethylene Glycol 2k-Angiopep-2); finally, the ROS response type co-delivery nano platform AO (at) PTP / 47aD is prepared and obtained. The co-delivery nano-platform prepared by the invention is relatively small in particle size, uniform in morphology and relatively high in biological safety, and has no obvious damage to various tissues and visceral organs. The glioblastomaimmunopotentiator can be used as a general platform for gene delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and can comprehensively overcome immune resistance of glioblastoma.
The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.
The present invention belongs to the field of molecular biology technology, and in particular relates to a recombinant protein of the CgVg functional domain DUF1943 and VWD of the long oyster, as well as a preparation method and application thereof. The amino acid sequence of the recombinant protein of the CgVg functional domain DUF1943 of the long oyster is shown in SEQ ID NO.1. The amino acid sequence of the recombinant protein of the CgVg functional domain VWD of the long oyster is shown in SEQ ID NO.2. The recombinant proteins of the CgVg functional domain DUF1943 and VWD of the long oyster obtained by the present invention have a wide range of binding activity against microorganisms, among which the DUF1943 recombinant protein has the activity of agglutinating bacteria and fungi, and the VWD recombinant protein has a broad spectrum of activity in inhibiting bacterial growth, and can be applied to the research and development of antibacterial drugs, immunopotentiators and feed additives for marine organisms.
The invention relates to the technical field of biological medicine, in particular to an immune synergist, an enhanced NK cell preparation, a preparation method and application. The immune synergist is hirudin, and the concentration of the hirudin is 10-40 [mu] g / ml. The enhanced NK cell preparation is prepared by the preparation method. According to the preparation method, the enhanced NK cell preparation is obtained after NK cells which are amplified in vitro for 14 days are pretreated by adopting the immune synergist. The application comprises an application of the immune synergist in up-regulation of expression of NK cell granzyme B and an application of the immune synergist in preparation of an NK cell preparation for inhibiting breast cancercell activity. The expression level of granzyme B of the NK cells can be safely and economically improved, and the in-vitro killing activity of the NK cells to breast cancer cells is remarkably enhanced.
The invention relates to the technical field of precipitation separation equipment, and discloses an immunopotentiator crude product precipitation separation device which comprises a precipitation tank used for precipitation separation of an immunopotentiator; the sealed tank body is used for being in sealed butt joint with the top of the precipitation tank body, and a feeding opening is formed in the top of the sealed tank body; the cleaning mechanism is used for covering the top of the precipitation tank body and cleaning the interior of the precipitation tank body; the lifting and rotating mechanism is used for switching butt joint of the sealing tank body or the cleaning mechanism and the settling tank body, the lifting and rotating mechanism is arranged between the sealing tank body and the cleaning mechanism, and the lifting and rotating mechanism is connected with the sealing tank body and the cleaning mechanism in a one-to-one mode through connecting rods. Maintenance and inspection are convenient, the daily maintenance process is greatly simplified, the working efficiency is improved, meanwhile, the mechanical damage risk possibly caused by frequent disassembly and assembly is reduced, and the service life of equipment is prolonged.
The invention discloses a gE fusion protein containing a gH Th epitope and a preparation method and application thereof, and relates to the technical field of biomedicine, the fusion protein comprises a varicella-zoster virus (VZV) glycoprotein E extracellular domain (gE) and a Th epitope-containing VZV glycoprotein H extracellular domain (gH) polypeptide. The gE fusion protein can be applied to VZV vaccines, and solves the technical problems of weak immunogenicity of gE antigens and serious side reaction of vaccines in vaccines prepared in the prior art. Compared with the Xinanlietaine, the vaccine taking the gE fusion protein as the antigen has the advantages that the variety and dosage of immunopotentiators are less, the immunogenicity is better, and the clinical side reaction is lower; besides, the gE fusion protein vaccine not only can induce a gE specific CMI reaction, but also can induce a gH specific CMI reaction, so that the effectiveness of the vaccine is further improved. In short, the gE fusion protein has good clinical application potential.
The invention is directed to compositions that include metal-complexed plant compounds. The compositions can be derived from liquid concentrates, extracts, and pomace from plants, such as fruits or vegetables. The compositions can further include additional nutraceutical antimicrobials, antioxidants, and immune boosters. The compositions can be administered to animals to increase animal health, reduce stress, reduce oxidative stress, maintain health, improve health, improve immunity, improve vaccinationefficacy, increase feed conversion rate, decrease pro-inflammatory cytokine levels, increase anti-inflammatory cytokines, or any combination thereof in an animal. The compositions of the invention exhibit enhanced bioavailability relative to control compositions that do not contain the metal-complexed compounds
The invention discloses an immunogenic composition containing gE virus-like nanoparticles as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises gE virus-like nanoparticles, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE virus-like nanoparticles comprise VZV gE, a linkerpeptide (SGS) and a VZV gI polypeptide containing a Th epitope. The immunogenic composition provided by the invention can be applied to VZV vaccines, and solves the technical problems of weak gE immunogenicity and serious vaccine side reaction in vaccines prepared in the prior art. The immunogenicity of the vaccine is better than that of Xinanliei, the use of an immunopotentiator is reduced, and the clinical side reaction is lower. In addition, the vaccine can also induce an obvious gI specific antibody, which is beneficial for further improving the effectiveness of the vaccine. In short, the immunogenic composition provided by the invention has good clinical application potential.